Advertisement
Advertisement
June 29, 2014
Spectranetics Completes Acquisition of AngioScore
June 30, 2014—Spectranetics Corporation announced that it has completed the acquisition of AngioScore Inc., for $230 million in cash, along with additional contingent commercial and regulatory milestone payments. Plans for the acquisition were first announced on May 27, 2014.
AngioScore develops and markets the AngioSculpt scoring balloon technology platform, which is a portfolio of devices to treat blockages in the coronary and peripheral vasculature, including critical limb ischemia, in-stent restenosis, calcified lesions, and chronic total occlusions. AngioScore is based in Fremont, California. Spectranetics is headquartered in Colorado Springs, Colorado.
Advertisement
Advertisement